Skip to content
Clinical Trials – home
Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Verified siteFast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial looks at people with newly diagnosed advanced ovarian cancer that is non‑HRD‑positive. After having received platinum‑based chemotherapy, participants may receive a maintenance treatment. The new drug being tested is Raludotatug Deruxtecan (MK-5909, R‑DXd), given by IV infusion, either alone or together with bevacizumab. These options are compared with the usual treatment that doctors give after chemotherapy, called standard of care.

The study’s purpose is to find out whether the new maintenance approach can keep the disease from getting worse longer and help participants live longer. Participants will receive the study medication every few weeks for up to about two years, and will have regular doctor visits, imaging scans that follow RECIST 1.1 criteria, and questionnaires that assess quality‑of‑life. The main outcomes measured are the time before the cancer progresses, known as progression‑free survival, and the length of overall survival, called overall survival. Throughout the trial, doctors will watch for any adverse events and record them.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Assignment

    After joining the study, you will be randomly placed into one of three groups: receiving raludotatug deruxtecan alone, receiving raludotatug deruxtecan together with bevacizumab, or receiving the standard treatment used for ovarian cancer.

  2. Step 2

    Baseline Assessments

    Before any medication is given, you will undergo a series of examinations that may include imaging scans, blood tests, and questionnaires about your quality of life. These assessments create a reference point for later comparisons.

  3. Step 3

    Start of Maintenance Treatment

    You will receive the assigned medication(s) by intravenous infusion. If you are assigned to the bevacizumab arm, the dose is 15 mg per kilogram of body weight. If you are assigned to the raludotatug deruxtecan arm, the infusion contains a concentration of 00 % (volume/volume). The exact timing of each infusion follows the study schedule.

  4. Step 4

    Repeated Treatment Cycles

    The infusion(s) will be repeated at regular intervals defined by the protocol, typically every few weeks, until the disease shows progression, side effects become unacceptable, or the study ends. Each cycle includes the same dose and method of administration as the first infusion.

  5. Step 5

    Ongoing Monitoring

    During the treatment period, you will have periodic imaging scans and blood tests to check the status of the cancer and your overall health. You will also complete quality‑of‑life questionnaires to record any changes in how you feel.

  6. Step 6

    Management of Adverse Events

    If any side effects occur, the study team will assess their severity. Depending on the assessment, the dose may be adjusted, supportive care may be provided, or treatment may be stopped if the side effects are severe.

  7. Step 7

    Study Completion

    The trial concludes when disease progression is documented, when treatment is discontinued because of side effects, or when the overall study end date is reached. At that time, final assessments and questionnaires will be performed.

Who can join the trial?

14 criteria

  • Must have a new diagnosis that a doctor has confirmed by looking at tissue under a microscope (histologically confirmed) of stage III or stage IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (cancers that start in the lining of these organs).
  • If you have HIV, your infection must be well‑controlled with medicines called antiretroviral therapy (ART).
  • If you test positive for hepatitis B surface antigen (HBsAg), you must have taken hepatitis B antiviral medicine for at least 4 weeks and have an undetectable hepatitis B viral load (no detectable virus) before randomisation.
  • If you have a history of hepatitis C, your hepatitis C viral load must be undetectable (no virus found in the blood).
  • You must have had either primary debulking surgery (PDS) or interval debulking surgery (IDS), which are operations to remove as much tumor as possible.
  • You must have finished at least 4 and no more than 6 cycles (treatment sessions) of first‑line (1L) platinum‑based chemotherapy (a common type of cancer‑killing drug that contains platinum).
  • Your doctor must judge that after the first‑line platinum chemotherapy you have a complete response (CR), partial response (PR), stable disease (SD), or no evidence of disease (NED) – meaning the cancer is gone or not getting worse.
  • If you plan to receive bevacizumab (a medicine that blocks blood vessel growth) as maintenance therapy, you must have already received at least 2 cycles of bevacizumab 15 mg/kg every 3 weeks (or an equivalent dose) together with the first‑line platinum chemotherapy, without any dose reductions.
  • Your doctor must decide that a PARP inhibitor (a type of targeted cancer drug) as maintenance therapy is not the preferred option for you, especially if your tumor is not HRD‑positive (does not have homologous recombination deficiency).
  • You must be able to give a sample of tumor tissue that has not been treated with radiation, so the study can test for cadherin‑6 (CDH6) and HRD status and other biomarkers.
  • If you have any side effects (adverse events, AEs) from previous cancer treatments, they must have improved to grade 1 or less (mild) or returned to baseline, except for hair loss (alopecia) or skin color changes (vitiligo), as judged by your doctor.
  • You must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which means you are fully active (0) or able to carry out light work (1), assessed within 7 days before randomisation.
  • You must be a female patient.
  • You must be an adult (generally 18 years of age or older).

Who cannot join the trial?

21 criteria

  • Has a type of ovarian cancer that is not the common serous or endometrioid high‑grade form, such as non‑epithelial cancers (germ‑cell or sex‑cord‑stromal tumors), borderline tumors (low malignant potential), mucinous or seromucinous tumors that are mostly mucinous, malignant Brenner’s tumor, or undifferentiated carcinoma.
  • Has not gotten better from a side effect (adverse event) caused by previous cancer treatment before being randomized.
  • Has had radiation therapy within the last 2 weeks, or still has radiation‑related problems that need steroid medicines.
  • Has received a live or weakened (live‑attenuated) vaccine within 30 days before the first study dose.
  • Plans to receive, or has already received, chemotherapy delivered directly into the abdomen (intraperitoneal chemotherapy) as first‑line (1L) treatment.
  • Is taking chronic steroids at a dose higher than 10 mg of prednisone (or an equivalent) each day.
  • Has already received first‑line platinum‑based chemotherapy without bevacizumab and currently shows only stable disease (SD) or a partial response (PR) when screened.
  • Has a test result for HRD (homologous recombination deficiency) that is positive, unknown, or unclear.
  • Has another cancer that is getting worse or needed active treatment in the past 3 years.
  • Has cancer that has spread to the brain or spinal cord (active central nervous system metastases) or has cancer cells in the lining of the brain (carcinomatous meningitis).
  • Has ever had interstitial lung disease (ILD) or pneumonitis, which are serious lung inflammations.
  • Has had a stroke, mini‑stroke (transient ischemic attack), or other serious blood‑clot problems (arterial thromboembolic events such as intestinal ischemia) within the past 6 months.
  • Has an active infection that needs treatment with medicines that affect the whole body (systemic therapy).
  • Has not fully recovered from major surgery or still has complications from surgery.
  • Has active inflammatory bowel disease (such as Crohn’s disease or ulcerative colitis) that needs medicines suppressing the immune system, or has a past history of these conditions.
  • Has uncontrolled or serious heart or blood‑vessel disease.
  • Has severe lung problems caused by other lung illnesses.
  • Has a current bowel blockage that is clinically important (including partial blockage, blockage related to the ovarian cancer, abdominal fistula, gut perforation, intra‑abdominal abscess, or evidence that the lower part of the colon is involved).
  • Has a recent (within 6 months) history of blood‑clot disorders, serious bleeding, coughing up blood (hemoptysis), or active gastrointestinal bleeding.
  • Is HIV‑positive and has a history of Kaposi’s sarcoma or multicentric Castleman disease.
  • Has stopped bevacizumab during first‑line platinum chemotherapy because of any side effect related to bevacizumab, making them ineligible to receive bevacizumab in this study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Bevacizumab

    is a medicine that helps stop new blood vessels from forming around tumors. By blocking these vessels, it can slow the growth of cancer. In this study, it is given through an IV infusion and is used either by itself or together with another drug to see if adding it improves the treatment results for women with newly‑diagnosed advanced ovarian cancer.

  • Raludotatug deruxtecan (R‑DXd)

    is an experimental cancer drug that carries a tiny amount of chemotherapy directly to cancer cells. It is also given by IV infusion. The trial is testing whether using this drug as a maintenance treatment after initial chemotherapy, with or without the addition of bevacizumab, can help patients live longer without the disease getting worse.

What is already known about the treatment

  • Bevacizumab

    This medication is given as an intravenous infusion, where a liquid solution is slowly injected into a vein. It is an approved drug that is widely used and described in many medical studies. It is mainly used to treat several cancers, including ovarian cancer, by blocking a protein that helps tumors grow new blood vessels. Bevacizumab is a monoclonal antibody that binds to VEGF‑A, stopping the signal that creates new blood vessels, and it belongs to the anti‑angiogenic drug class.

  • Raludotatug deruxtecan

    This drug is also administered by intravenous infusion, delivered directly into the bloodstream as a solution. It is currently an investigational medicine that is being studied in clinical trials and is not yet approved for general use. It is being tested as a maintenance treatment for newly diagnosed advanced ovarian cancer, aiming to keep the disease from returning after initial chemotherapy. Raludotatug deruxtecan is an antibody‑drug conjugate that attaches a chemotherapy payload to an antibody that seeks out cancer cells, delivering the toxic agent directly to the tumor, and it is classified as a targeted cytotoxic therapy.

Investigated diseases

Ovarian cancer - Ovarian cancer is a type of cancer that begins in the cells of the ovaries, the reproductive organs that produce eggs. It often starts as a small tumor that may not cause symptoms. Over time the cancer cells can grow and break away, spreading to nearby pelvic structures and the lining of the abdomen. The disease may then involve the peritoneal cavity, leading to fluid accumulation and involvement of other abdominal organs. In some cases, cancer cells travel through the bloodstream or lymphatic system to distant parts of the body.
Trial detailsLast updated 20 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-524592-22-00Protocol codeMK-5909-006Estimated enrolment674 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.